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Epigenetics is the study of all mechanisms that regulate gene transcription and genome stability that are maintained throughout the
cell division, but do not include the DNA sequence itself. The best-studied epigenetic mechanism to date is DNA methylation, where
methyl groups are added to the cytosine base within cytosine–guanine dinucleotides (CpG sites). CpGs are frequently clustered in
high density (CpG islands (CGIs)) at the promoter of over half of all genes. Current knowledge of transcriptional regulation by DNA
methylation centres on its role at the promoter where unmethylated CGIs are present at most actively transcribed genes, whereas
hypermethylation of the promoter results in gene repression. Over the last 5 years, research has gradually incorporated a broader
understanding that methylation patterns across the gene (so-called intragenic or gene body methylation) may have a role in
transcriptional regulation and efficiency. Numerous genome-wide DNA methylation profiling studies now support this notion,
although whether DNA methylation patterns are a cause or consequence of other regulatory mechanisms is not yet clear. This
review will examine the evidence for the function of intragenic methylation in gene transcription, and discuss the significance of this in
carcinogenesis and for the future use of therapies targeted against DNA methylation.
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One of the principal epigenetic mechanisms that governs the
transcriptional regulation of genes is the methylation of CpG
dinucleotides. DNA methylation at the promoter regions is known
to be important in both development and human disease,
including cancer. CpG sites tend to cluster in higher densities at
promoter regions than throughout the rest of the genome, which
has led to the definition of the term, CpG island (CGI; Bird, 1986).
These promoter-associated CGIs tend to be unmethylated (Takai
and Jones, 2002), whereas up to 80% of the total number of CpG
sites in a genome are methylated. Furthermore, CpG sites are also
found at significantly higher densities in gene-rich compared with
gene-poor areas of the human chromosomes (Weber et al, 2005).
DNA methylation at promoter CpG sites leads to the repression of
gene expression by altering the conformation of DNA itself and
local histone structures (Ng and Bird, 1999; Cedar and Bergman,
2009). Dogma states that this prevents the recruitment of the
transcription complex scaffolding that can activate RNA polymer-
ase II. However, this mechanism has only been thought to account
for the transcriptional control in approximately half of all genes,
and this figure may indeed be as low as a subset of 200 genes in any
given cell type (Weber et al, 2005). It is possible that other
unexplored functions of DNA methylation have additional roles in
the transcriptional process of genes that do not contain a
promoter-associated CGI.
In cancers, a substantial proportion of genes with promoter-
associated CGIs become hypermethylated (Jones and Baylin, 2007).
Promoter hypermethylation frequently silences tumour-suppres-
sor genes in cancers. Indeed, profiling of specific sites or panels of
sites that are aberrantly methylated within tumour cells are
currently being investigated as biomarkers of early prediction and
prognostication, where cancer-associated methylation can be
detected in tumour biopsy samples, cell-free serum, urine and
peritoneal fluid (Schulz and Goering, 2011). Furthermore, DNA
methylation profiling can also be used to define novel tumour
subgroups (Flanagan, 2011).
A further understanding of the epigenetic mechanisms that
regulate gene transcription in pathological states such as cancer
will be crucial in the development of novel and innovative
therapies for these diseases. Already, promoter hypermethylation
can be reversed by non-specific demethylating agents, such as
decitabine and 5-azacytidine (5-aza), which have been approved in
the therapy of several haematological malignancies (Fandy et al,
2007). Few clinical trials of demethylating agents in solid tumours
have been performed. To date, the largest phase 1 study in solid
tumours suggested that the doses required to produce the same
effects in humans as in mice were tolerable (Appleton et al, 2007),
but as yet solid tumour demethylating therapies have not been
successful in humans. The first published phase 2a trial suggested
that azacytidine could help to reverse the platinum-based drug
resistance in the patients with ovarian cancer (Fu et al, 2011).
Although the intention of demethylating agents is to reactivate
promoters that are silenced by promoter hypermethylation, the
entire genome could become demethylated, including intragenic
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sequences. Recent investigations have also suggested that 5-aza has
broader effects than purely as a demethylating agent, including
altering activating histone modifications to repressive marks,
and expression changes independent of promoter methylation
(Komashko et al, 2008). However, this study only examined
promoter regions and further insights may be gained by
investigating the intragenic effects of demethylating agents on
both histone and DNA methylation. The temporal nature of these
events also requires further investigation. Therefore, understand-
ing the role of intragenic methylation (IGM) in transcription and
in carcinogenesis is critical to understand the full consequences of
chemically induced demethylation as a therapy.
IGM IN LOWER ORGANISMS
Clues regarding the role of IGM in a variety of organisms emerged
over a decade ago (Yoder et al, 1997). The basic patterns of IGM
are widely conserved throughout the plant and animal kingdoms
(Feng et al, 2010; Zemach et al, 2010). In 2006, the first high-
resolution genome-wide analysis of the methylation of CpG sites in
Arabidopsis thaliana revealed that over one third of the genes had
high levels of IGM, but only 5% of genes had high promoter region
methylation (Zhang et al, 2006). A year later, Zilberman et al
(2007) established a correlation between DNA methylation and the
rate of gene transcription across the whole genome of Arabidopsis.
Genes in the plant that were expressed at higher levels (in the top
three deciles) tended to have higher levels of IGM than genes
expressed at low levels, and all genes had low levels of methylation
in the flanking regions (Figure 1). They hypothesised that the role
of DNA methylation of the gene body was to suppress the
unwanted expression of non-coding RNAs (ncRNAs) and the
expression of transposons, which are epigenetically silenced in
plants to reduce genomic instability. Frequently expressed genes
would have higher levels of IGM in order to reduce the chance of
aberrant ncRNAs being expressed or alternative intragenic
promoters being active, in comparison with the genes that are
expressed less frequently. The length of the gene was also
important; shorter genes with higher levels of IGM levels are less
likely to be expressed, whereas IGM appeared to have fewer
transcriptional effects in longer genes. This may be principally
because the effect of methylation on transcription is greatest at the
extreme 50 and 30 ends of the gene.
THE ROLE OF IGM IN HUMANS
Several reports have now demonstrated a similar link in humans
between the patterns of IGM and expression to those shown in
lower organisms (Hellman and Chess, 2007; Ball et al, 2009; Rauch
et al, 2009; Aran et al, 2011). In 2007, Hellman and Chess used an
array approach to show the pattern of methylation across the X
chromosome to investigate X-linked gene silencing. Contrary to
their expectations, the active X allele was found to have higher
levels of methylation than the silenced X allele, and 49% of the
array probes were in intragenic coding regions of known genes.
Furthermore, there was no bias towards methylation of repetitive
elements in genes, which would have supported the hypothesis that
the role of IGM is to suppress repetitive element transcription.
Rauch et al (2009) used an enrichment technique for genome-wide
methylated DNA to map methylation across the genome of human
B cells. They confirmed that methylated intragenic regions
correlated with higher levels of gene transcription, and IGM may
be a mechanism that regulated the use of alternative promoters.
This hypothesis gained supportive evidence from a study that
examined DNA methylation in a specific genomic region in the
human brain tissues, (Maunakea et al, 2010), discussed later in this
review.
A further genome-wide study conducted in different human
tissues showed a correlation between the rate of cell division
between actively expressed and inactive genes and IGM (Aran et al,
2011), which mirrored the pattern previously found by Zilberman
et al (2007). Furthermore, active and inactive genes in dormant
tissue types, such as the brain and lung, were found to have
unmethylated promoters and highly methylated intragenic regions,
whereas methylation levels were reduced in inactive genes in
rapidly dividing tissues such as the placenta and lymphocytes.
The precise definition of a promoter region is being redefined by
new evidence that demonstrates the methylated state of the distal
promoter region, and indeed extensions into the gene body, is
relevant to the expression state of the gene. Appanah et al (2007)
showed that the 30 region of gene promoters had to be
unmethylated to enable efficient transcriptional elongation.
Recently, Hodges et al (2011) demonstrated hypomethylated
regions (HMRs) that extended into the shore regions around
promoters, as well as intragenic HMRs. Although the functions of
these HMRs are unknown, the intragenic regions are associated
with transcription factor binding sites, which suggest a biologically
significant role.
The genomes of cancer cells also tend to show global
hypomethylation alongside hypermethylation of the gene promo-
ters. The latter has deleterious effects due to the silencing of
tumour-suppressor genes and consequent acceleration in the
oncogenic process. The causal mechanisms for genomic hypo-
methylation are still unknown, but a recent analysis suggests that it
is unlikely to be due to a dysregulation in DNA repair mechanisms
or members of the DNA methyltransferase (DNMT) enzyme family
(Wild and Flanagan, 2010). The consequences of hypomethylation,
whether intergenic or intragenic, are also unclear, but may act in a
similar manner to that postulated in plant intragenic sequences,
where demethylation leads to the reactivation of repressed
repetitive elements, and potentially further genomic instability.
Specific IGM sites have already been implicated in several human
cancers. Salem et al studied a panel of cells from human bladder
and colon cancers, and found a 550-bp-long HMR of the intragenic
region of the PAX6 gene, which mapped to exon 5. PAX6 is a
highly conserved protein, which is important during embryogen-
esis and acts to stimulate uncontrolled cell growth. With the use of
transfection studies, they showed that hypermethylation of exon 5
did not impede gene expression, but PAX6 protein levels fell when
the promoter region was hypermethylated. In 2007, Smith et al
(2007) identified aberrantly methylated areas within non-promoter
CGI sites in the genes associated with colonic carcinoma, which
appear to have a functional role by affecting mRNA transcription.
These few studies have shown the value of investigating regions of
DNA methylation in the areas outside of CGIs.
Data on the role and pattern of IGM in specific cancer types are




















Figure 1 A schematic of the correlation determined by Zilberman
et al for the methylation levels of differentially expressed genes.
Abbreviations: TSS, transcription start site; 30 UTR, three-prime untrans-
lated region.
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group’s work, the distribution of hypomethylated CpG sites in
primary tumours and cell lines has been shown to be clustered in
gene-poor chromosomal regions, at the 50 region of frequently
expressed genes (including the promoter, first exon and first
intron), and large intragenic regions of hypomethylation at
chromosomal breakpoints, large genes and tissue-specific gene
clusters (Shann et al, 2008). Further work that compares these data
with normal tissue samples is required to determine the
significance of this finding in cancer cells. We have previously
shown significant variability in peripheral blood DNA methylation
in the intragenic gene sequences in bilateral breast cancer cases
compared with matched healthy control individuals using a
tiled microarray (Flanagan et al, 2009). Most of the variability
was found in intragenic repetitive elements, and one repetitive
element in the ATM gene was associated with a three-fold
increased risk of breast cancer in a larger case–control study.
These data show potential biomarkers exist in the intragenic
sequences of genes.
The first genome-wide sequencing study of a bisulphite-
converted DNA sample from circulating white blood cells of a
single individual was recently published (Li et al, 2010). These
data, which is publically available, enable the genome-wide DNA
methylation analysis of candidate genes of interest. Of particular
interest in breast cancer is the ESR1 gene, which encodes the
oestrogen receptor alpha protein, which we have used to illustrate
intragenic DNA methylation from whole-genome bisulphite
sequencing data. The expression of ESR1 is of significant biological
and prognostic importance in breast cancer, and largely drives the
determination of the management plan. ESR1-positive tumours
have broadly better outcomes, with slower-growing tumours on
the whole, fewer metastases, and a greater range of hormonally
targeted treatment options including tamoxifen and the aromatase
inhibitors. Methylation data of the ESR1 gene shows the typical
pattern of methylation, with an unmethylated promoter and a
highly methylated intragenic region (Figure 2A). Genome-wide
bisulphite sequencing data have now been published for
embryonic stem cells (H1 and hESCs), fibroblast cell lines
(IMR90, fibroblasts) and ESCs induced to differentiate into
fibroblasts (hESC-fibroblasts; GEO records: GSE19418 and
GSE16256 (Figure 2B); http://www.ncbi.nlm.nih.gov/geo/). Infor-
mation from further cell types will soon become available through
projects such as the NIH Epigenomics Roadmap Project (http://
www.roadmapepigenomics.org/). Further work is ongoing in our
laboratory to discern the significance of the molecular mechanisms
that underlie this pattern and its correlation with expression, and
whether specific CpG sites across the ESR1 gene may act as
biomarkers. Although there are numerous ongoing studies for
predictive and diagnostic biomarker CpG sites in the promoter
region, the potential goldmine of information in intragenic regions
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Figure 2 (A) Methylation levels of each CpG site (grey circles) along the full length of the ESR1 gene from the transcription start site (indicated by ‘0’
on the x axis). The exons are shown along the uppermost horizontal line as full black circles. The black line indicates the smoothed average methylation
levels across the gene. The data were obtained from the bisulphite sequencing study of peripheral mononuclear cells by Li et al (2010). (B) Genome-wide
studies of human embryonic stem cells (ESCs, solid) and lung-derived fibroblasts (dotted) showed different patterns of IGM in the ESR1 gene, and a broadly
unmethylated promoter region. In ESCs that had differentiated into fibroblasts (dashed), the pattern of IGM bore a greater similarity to the adult
differentiated pattern (IMR90 cell line, adult fibroblasts) than wild-type ESCs. The exons are shown along the uppermost horizontal line as full black circles,
with x axis showing the log scale genomic location.
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POSTULATED FUNCTIONS OF INTRAGENIC DNA
METHYLATION: CAUSE OR CONSEQUENCE?
Given the conservation of methylation patterns across genes in
both plants and animals (Suzuki and Bird, 2008; Feng et al, 2010),
it is likely that gene-related DNA methylation is an ancient product
of evolution that occurred before these kingdoms diverged, which
is evidence of an important function. Early studies recognised the
increased level of CpG in transposons, and postulated that the
primary role of the methylation of repetitive elements was to
suppress the expression of these parasitic insertions (Yoder et al,
1997). However, other mechanisms have now been proposed.
Intragenic CpG methylation may act to repress the initiation of
transcription from alternative transcription start sites. Maunakea
et al (2010) generated a CpG ‘map’, which included B88% of the
genomic CpG sites, and then assessed the locations of methylated
CpG sites in tissue from human brain tissue. CpG sites in
intragenic, intergenic and promoter regions were found to overlap
with sites of transcriptional initiation. The differential methylation
levels of these three regions was postulated to correlate with the
transcription of alternative isoforms in different tissue types,
depending on the transcription start site that was unmethylated.
However, the authors acknowledge that this genome-wide
approach to the data analysis may prevent the recognition
of smaller-scale regulatory mechanisms of DNA methylation.
A similar mechanism that has been proposed relates to the
modification of the transcriptional efficiency of RNA polymerase II
and the transcriptional complex (Lorincz et al, 2004). This could
be mediated by the modulation of the regional chromatin structure
and may explain why there is a differential pattern of methylation
in actively dividing tissues vs dormant tissues.
An alternative hypothesis is that methylation of the DNA along
the sense strand could suppress the expression of antisense strand
mRNA, either as full-length ncRNA transcripts or microRNAs,
being initiated from a variety of intragenic sites. These antisense
strands might interfere with the transcription of sense RNA due to
their complementarity (Tufarelli et al, 2003), whereby higher levels
of antisense copies lead to binding between the sense and antisense
strands, reducing the amount of free sense mRNA and conse-
quently reducing the protein translation, in a similar manner to
microRNA-mediated gene regulation.
Any hypothesis that accounts for the effects of DNA methylation
must take into account the effect of nucleosomes, the constituents
of chromatin that package DNA. Nucleosomes consist of an
octomer of four histone types (H2A, H2B, H3 and H4), which is
wrapped around by a 147-bp DNA. Histone variants have variable
affinities for different DNA sequence motifs, including methylated
DNA (Segal and Widom, 2009). Histone modifications act locally
to either repress or enable transcription. Such modifications
include the methylation, acetylation and sumoylation of amino-
acid residues on histone tails that extend out from the protein core.
CpG density has been found to correlate with specific histone
marks, which may have importance in the efficiency of the
transcription complex across the gene (Lorincz et al, 2004; Lieb
and Clarke, 2005).
The interaction between histone modifications and the intra-
genic DNA methylation, whether cause or consequence, is still
unclear and currently being investigated. For example, the
H3K36me3 histone mark is enriched at the regions of high CpG
density (Hahn et al, 2011). H3K36me3 has been associated with
hypermethylated DNA in the intragenic regions of actively
expressed genes, where this mark may act to recruit DNMTs and
maintain the methylated state (Hawkins et al, 2010). Intragenic
H3K36 methylation has been shown in yeast to inhibit gene
transcription from alternative start sites (Carrozza et al, 2005).
There is some evidence of specific types of histones at exonic
regions compared with intronic (Lieb and Clarke, 2005; Huff et al,
2010), including the H3K36me3 mark at the exons of highly
expressed genes (Choi, 2010). Interestingly, Hahn et al (2011)
indicated that the changes in intragenic DNA methylation levels
did not affect the H3K36 histone modification locally and that the
alternative reduction of H3K36 methylation by siRNA knockdown
of SETD2 did not alter the intragenic DNA methylation. These data
support the hypotheses that DNA methylation either occurs as a
consequence of the chromatin environment only in some genes, or
that two redundant and independent systems of gene repression
have evolved. However, these data do not yet provide an answer to
the question of cause or consequence, particularly at an individual
gene level.
Certain types of histone modifications are associated with
aberrant patterns of DNA methylation in cancer. Tri-methylated
H3K9 (H3K9me3) and H3K27me3 are repressive histone
modifications. H3K9me3 at the promoter region is associated
with gene repression in plants, fungi and mammals, although the
most recent evidence suggests that it does not affect the efficiency
of transcription (Blahnik et al, 2011). The polycomb-associated
repressive mark, H3K27me3, is found at aberrantly hypermethy-
lated promoters in both cancer cell lines and tumour samples,
where it appears to be preceded by an aberrant DNA methylation
signature in inflamed tissues (Hahn et al, 2008). It may be that a
form of epigenetic switching occurs at promoters to repress the
gene transcription permanently, as DNA methylation replaces the
more easily modifiable histone marks (Gal-Yam et al, 2008), but
their interactions with DNA methylation across the gene body
remain largely unexplored. Indeed, many of the commonly studied
histone modifications at promoter regions, such as the activating
mark, H3K4me3 that prevents DNA methylation at the promoter,
have not been studied in depth across the gene body in tumour
cells, although numerous studies have shown their relationship
with the gene body in normal fetal and adult cell types (Guenther
et al, 2007). As yet we can only speculate on the nature of the full
interactions between histone modifications and DNA methylation
in neoplastic states.
Nucleosome composition at the 50 region of the gene, within the
intragenic region, is of great importance in determining whether
the gene is transcribed (reviewed in Lieb and Clarke (2005)).
Typical patterns of methylation exist, such as the one shown in
Figure 2, which demonstrate a steep increase in methylation levels
within the first 8 kb from the transcription start site in actively
expressed genes (Zilberman et al, 2007; Aran et al, 2011). Such
patterns suggest that the first few nucleosomes in genes may be
highly important for transcriptional efficiency. How this is affected
by gene length and transcriptional activity remains unclear, but the
recent publication by Han et al (2011) describes an exciting new
strategy for the investigation of the temporal sequence of
nucleosome occupancy, termed Nucleosome Occupancy Methy-
lome Sequencing (NOME-Seq; Komashko and Farnham, 2010;
Nanty et al, 2011). DNA methylation at the loci studied with
NOME-Seq appears to occur after nucleosome positioning, and
may be influenced by transcription factors, polycomb proteins and
other chromatin remodelling factors. Choi et al (2009) also
illustrated different levels of nucleosome occupancy and CpG
density at the start and end of each exon in the majority of protein-
coding genes, which may regulate the pausing of RNA polymerase
II at these sites as it traverses the gene.
A recent study demonstrated a link between replication timing
and IGM levels, where early replicating genes tended to be active
and had higher levels of IGM (Aran et al, 2011). This study also
showed a correlation between the rate of cell division between
actively expressed and inactive genes, and IGM, which mirrored
that pattern previously found by Zilberman et al (2007).
Furthermore, active and inactive genes in dormant tissue types,
such as the brain and lung, were found to have unmethylated
promoters and highly methylated intragenic regions, whereas
methylation levels were reduced in inactive genes in rapidly
dividing tissues such as the placenta and lymphocytes. This
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preliminary data indicate a link between levels of intragenic DNA
methylation and cell proliferation, but does not directly relate to
the causality of increased proliferation in cancer cells.
In summary, there are several alternative hypotheses for the
association between intragenic DNA methylation and transcrip-
tion, including modifying transcription efficiency, altering the
local histone conformation and producing different levels of sense
and antisense mRNA. There is currently more data to support the
hypothesis that intragenic DNA methylation is a consequence of
other mechanisms of transcriptional regulation, including histone
modifications, nucleosome positioning and replication timing.
Nevertheless, DNA methylation remains an important marker of
intragenic transcriptional efficiency and is experimentally easier to
study. Interestingly, recent evidence suggested that variable
methylation levels of individual CpG sites affect the binding
affinity of transcription factors to nearby binding sites (Flower
et al, 2010; Rishi et al, 2010). This may offer a further mechanism
by which specific intragenic CpG sites can affect transcription.
FUTURE PERSPECTIVES
Most of the work has focussed on CGI-associated methylation, as it
is relatively easy to target short regions of DNA for investigation,
such as promoter regions. Furthermore, the complexity and the
cost of genome-wide, or even chromosomal-wide, studies of
epigenetic mechanisms have been prohibitive until recently. With
improvements in next generation whole genome bisulphite
sequencing, including reduced costs and increased analysis speeds,
new insights are being gained rapidly. As more cell types are
bisulphite sequenced and published in freely available databases,
and as more individuals are analysed, the challenges ahead will be
in ensuring the depth of sequence reads and computational
handling are optimised for the analysis of such high volumes of
data. Only when these challenges are met will verifiable novel
insights into the mechanisms of DNA methylation transcriptional
control be possible. By studying CGI promoters exclusively,
we have only scratched the surface of the epigenetic landscape of
normal and cancer cells. Demethylating agents, including 5-
azacytidine, are already being used in the management of
haematological malignancies and myelodysplastic syndrome, and
are in clinical trials for multiple solid tumours. The ability to target
specifically aberrant regions of methylation in cancer cells holds
promise for truly personalised therapies. However, a thorough
understanding of the basic mechanisms of DNA methylation in
transcriptional control, including the role of IGM, is critical to fully
understand the consequences and side effects of such treatments.
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